Gilead Sciences, Inc. (GILD)

NMS – Real vaqt narxi. Valyuta: USD

134.94

+1.42 (1.06%)

Yopilishda: May 12, 2026, 4:00 PM EDT

08.05.2026

GILD Beats Q1 Earnings and Sales Estimates, Lowers '26 EPS View

GILD beats Q1 estimates as HIV and Trodelvy sales rise, but shares slip after the company cuts its 2026 EPS outlook.

08.05.2026

Gilead Sciences, Inc. (GILD) Q1 2026 Earnings Call Transcript

07.05.2026

Gilead (GILD) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates

Although the revenue and EPS for Gilead (GILD) give a sense of how its business performed in the quarter ended March 2026, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

07.05.2026

Gilead Sciences (GILD) Tops Q1 Earnings and Revenue Estimates

Gilead Sciences (GILD) came out with quarterly earnings of $2.03 per share, beating the Zacks Consensus Estimate of $1.89 per share. This compares to earnings of $1.81 per share a year ago.

07.05.2026

Gilead Sciences Expects Loss This Year on Acquired R&D Expenses

The biopharmaceutical company said it expects a 2026 adjusted loss of between $1.05 and 65 cents a share, compared with prior guidance of adjusted earnings between $8.45 and $8.85 a share.

07.05.2026

Gilead raises 2026 sales forecast, cuts profit outlook due to acquisitions

Gilead Sciences on Thursday posted a higher-than-expected first-quarter profit and raised its outlook for 2026 sales, but said it now expects a loss for the year due to ‌charges and financing costs related to recent acquisitions.

07.05.2026

Gilead Sciences Announces First Quarter Financial Results

FOSTER CITY, Calif.--(BUSINESS WIRE)-- #Earnings--Gilead Sciences, Inc. (Nasdaq: GILD) announced today its results of operations for the first quarter 2026. “Gilead teams have delivered another strong quarter with 8% year-over-year growth in our base business and 10% growth in HIV, supported by the successful launch of Yeztugo. We have raised our full year revenue guidance as a reflection of our performance," said Daniel O'Day, Gilead's Chairman and Chief Executive Officer. “Building on the strongest pipel.

Gilead's Earnings Skyrocket as Florida's AIDS Drug Program Falters, says AHF

LOS ANGELES--(BUSINESS WIRE)-- #AHFcares--Gilead's Earnings per Share Expected to Be Up 52% as Florida's and other States' AIDS Drug Programs Falters, says AHF.

29.04.2026

U.S. FDA Grants Priority Review of New Drug Application for Gilead's Once-Daily HIV Treatment of Bictegravir Plus Lenacapavir

FOSTER CITY, Calif.--(BUSINESS WIRE)-- #GILD--Gilead Sciences, Inc. (Nasdaq: GILD) today announced the U.S. Food and Drug Administration (FDA) accepted its New Drug Application (NDA) submission for bictegravir 75 mg/lenacapavir 50 mg (BIC/LEN) – an investigational, once-daily single-tablet combination regimen for the treatment of HIV in adults who are virologically suppressed. The FDA has granted priority review of the application and assigned a Prescription Drug User Fee Act (PDUFA) action date of Aug.

28.04.2026

Gilead Sciences Completes Acquisition of Arcellx Ahead of Potential Commercial Launch of Anito-cel

FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today announced the successful completion of its previously announced acquisition of Arcellx, Inc. (Nasdaq: ACLX). Under the terms of the transaction, Gilead acquired Arcellx for $115 per share in cash, plus one non‑transferable contingent value right (CVR) of $5 per share, representing a total implied equity value of approximately $7.8 billion at the time of closing. The acquisition builds on Kite, a Gilead Company, and.

Gilead Sciences, Inc. (GILD)

Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

Finranks

Kompaniya

Biz bilan bog'lanish

Bizni kuzating

Gilead Sciences, Inc. (GILD)

GILD Beats Q1 Earnings and Sales Estimates, Lowers '26 EPS View

Gilead Sciences, Inc. (GILD) Q1 2026 Earnings Call Transcript

Gilead (GILD) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates

Gilead Sciences (GILD) Tops Q1 Earnings and Revenue Estimates

Gilead Sciences Expects Loss This Year on Acquired R&D Expenses

Gilead raises 2026 sales forecast, cuts profit outlook due to acquisitions

Gilead Sciences Announces First Quarter Financial Results

Videolar

Press-relizlar

Gilead Sciences Announces First Quarter Financial Results

Gilead's Earnings Skyrocket as Florida's AIDS Drug Program Falters, says AHF

U.S. FDA Grants Priority Review of New Drug Application for Gilead's Once-Daily HIV Treatment of Bictegravir Plus Lenacapavir

Gilead Sciences Completes Acquisition of Arcellx Ahead of Potential Commercial Launch of Anito-cel

GILD Beats Q1 Earnings and Sales Estimates, Lowers '26 EPS View

Gilead Sciences, Inc. (GILD) Q1 2026 Earnings Call Transcript

Gilead (GILD) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates

Gilead Sciences (GILD) Tops Q1 Earnings and Revenue Estimates

Gilead Sciences Expects Loss This Year on Acquired R&D Expenses

Gilead raises 2026 sales forecast, cuts profit outlook due to acquisitions

Gilead Sciences Announces First Quarter Financial Results

Videolar

Press-relizlar

Gilead Sciences Announces First Quarter Financial Results

Gilead's Earnings Skyrocket as Florida's AIDS Drug Program Falters, says AHF

U.S. FDA Grants Priority Review of New Drug Application for Gilead's Once-Daily HIV Treatment of Bictegravir Plus Lenacapavir

Gilead Sciences Completes Acquisition of Arcellx Ahead of Potential Commercial Launch of Anito-cel

Search stocks

Gilead Sciences, Inc. (GILD)

Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

Finranks

Kompaniya

Biz bilan bog'lanish

Bizni kuzating

Gilead Sciences, Inc. (GILD)

GILD Beats Q1 Earnings and Sales Estimates, Lowers '26 EPS View

Gilead Sciences, Inc. (GILD) Q1 2026 Earnings Call Transcript

Gilead (GILD) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates

Gilead Sciences (GILD) Tops Q1 Earnings and Revenue Estimates

Gilead Sciences Expects Loss This Year on Acquired R&D Expenses

Gilead raises 2026 sales forecast, cuts profit outlook due to acquisitions

Gilead Sciences Announces First Quarter Financial Results

Videolar

Press-relizlar

Gilead Sciences Announces First Quarter Financial Results

Gilead's Earnings Skyrocket as Florida's AIDS Drug Program Falters, says AHF

U.S. FDA Grants Priority Review of New Drug Application for Gilead's Once-Daily HIV Treatment of Bictegravir Plus Lenacapavir

Gilead Sciences Completes Acquisition of Arcellx Ahead of Potential Commercial Launch of Anito-cel

GILD Beats Q1 Earnings and Sales Estimates, Lowers '26 EPS View

Gilead Sciences, Inc. (GILD) Q1 2026 Earnings Call Transcript

Gilead (GILD) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates

Gilead Sciences (GILD) Tops Q1 Earnings and Revenue Estimates

Gilead Sciences Expects Loss This Year on Acquired R&D Expenses

Gilead raises 2026 sales forecast, cuts profit outlook due to acquisitions

Gilead Sciences Announces First Quarter Financial Results

Videolar

Press-relizlar

Gilead Sciences Announces First Quarter Financial Results

Gilead's Earnings Skyrocket as Florida's AIDS Drug Program Falters, says AHF

U.S. FDA Grants Priority Review of New Drug Application for Gilead's Once-Daily HIV Treatment of Bictegravir Plus Lenacapavir

Gilead Sciences Completes Acquisition of Arcellx Ahead of Potential Commercial Launch of Anito-cel